Online inquiry

IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13526MR)

This product GTTS-WQ13526MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MCAM gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_006500.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4162
UniProt ID P43121
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13526MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14990MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ15978MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ13986MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ11886MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MLN-0264
GTTS-WQ4904MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BYM338
GTTS-WQ15330MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ6793MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA DS-8201
GTTS-WQ962MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-323
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.